1. Scrip
  2. >>Business
  3. >>Earnings

Top 10 Best-Selling Drugs Of Q1 2023: Keytruda Topples Humira

COVID-19 Products And Humira Decline As Keytruda Continues Ascent

 
• By Eleanor Malone

A review of the top-selling drugs of the first quarter of 2023 demonstrate the declining turnover from products to treat or prevent COVID-19, as well as a precipitative drop by Humira. Merck & Co’s PD-1 inhibitor Keytruda grew strongly, and Novo Nordisk’s injectable diabetes drug Ozempic burst into the top 10 ranks.

rising line on graph with hand pointing to peak
Keytruda sales continue towards peak • Source: Shutterstock Lemonsoup14

The top 10 best-selling drugs of the first quarter of 2023 generated total revenues of $33.0bn, down from $46.3bn a year earlier.

The sharp drop reflected the declining influence of COVID-19. In the first quarter of 2022, the highest revenue-generating vaccines for COVID-19, Pfizer Inc./BioNTech SE’s Comirnaty and Moderna, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business